198 related articles for article (PubMed ID: 35304461)
1. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy.
Li J; Shu X; Xu J; Su SM; Chan UI; Mo L; Liu J; Zhang X; Adhav R; Chen Q; Wang Y; An T; Zhang X; Lyu X; Li X; Lei JH; Miao K; Sun H; Xing F; Zhang A; Deng C; Xu X
Nat Commun; 2022 Mar; 13(1):1481. PubMed ID: 35304461
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
Shu X; Li J; Chan UI; Su SM; Shi C; Zhang X; An T; Xu J; Mo L; Liu J; Wang Y; Li X; Deng M; Lei JH; Wang C; Tian H; Heng S; Shim JS; Zhang X; Dai Y; Yao Z; Kuang X; Lin Y; Deng CX; Xu X
Cancer Res; 2023 Aug; 83(15):2614-2633. PubMed ID: 37227919
[TBL] [Abstract][Full Text] [Related]
3. Mutations in
Samstein RM; Krishna C; Ma X; Pei X; Lee KW; Makarov V; Kuo F; Chung J; Srivastava RM; Purohit TA; Hoen DR; Mandal R; Setton J; Wu W; Shah R; Qeriqi B; Chang Q; Kendall S; Braunstein L; Weigelt B; Blecua Carrillo Albornoz P; Morris LGT; Mandelker DL; Reis-Filho JS; de Stanchina E; Powell SN; Chan TA; Riaz N
Nat Cancer; 2021 Dec; 1(12):1188-1203. PubMed ID: 33834176
[TBL] [Abstract][Full Text] [Related]
4. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.
Yang Q; Li X; Chen H; Cao Y; Xiao Q; He Y; Wei J; Zhou J
Oncogene; 2017 May; 36(21):2969-2980. PubMed ID: 28092673
[TBL] [Abstract][Full Text] [Related]
5. S100A9 Regulates MDSCs-Mediated Immune Suppression via the RAGE and TLR4 Signaling Pathways in Colorectal Carcinoma.
Huang M; Wu R; Chen L; Peng Q; Li S; Zhang Y; Zhou L; Duan L
Front Immunol; 2019; 10():2243. PubMed ID: 31620141
[TBL] [Abstract][Full Text] [Related]
6. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
7. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
9. S100A9 maintains myeloid-derived suppressor cells in chronic sepsis by inducing miR-21 and miR-181b.
Alkhateeb T; Kumbhare A; Bah I; Youssef D; Yao ZQ; McCall CE; El Gazzar M
Mol Immunol; 2019 Aug; 112():72-81. PubMed ID: 31078118
[TBL] [Abstract][Full Text] [Related]
10. iPSC-Derived Hereditary Breast Cancer Model Reveals the
Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753
[TBL] [Abstract][Full Text] [Related]
11. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
12. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939
[TBL] [Abstract][Full Text] [Related]
13. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
14. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
15. S100a9 Protects Male Lupus-Prone NZBWF1 Mice From Disease Development.
Davison LM; Alberto AA; Dand HA; Keller EJ; Patt M; Khan A; Dvorina N; White A; Sakurai N; Liegl LN; Vogl T; Jorgensen TN
Front Immunol; 2021; 12():681503. PubMed ID: 34220829
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-induced SDF-1α production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment.
Ouyang L; Chang W; Fang B; Qin J; Qu X; Cheng F
Sci Rep; 2016 Dec; 6():39541. PubMed ID: 27996037
[TBL] [Abstract][Full Text] [Related]
17. Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer.
Kwak T; Wang F; Deng H; Condamine T; Kumar V; Perego M; Kossenkov A; Montaner LJ; Xu X; Xu W; Zheng C; Schuchter LM; Amaravadi RK; Mitchell TC; Karakousis GC; Mulligan C; Nam B; Masters G; Hockstein N; Bennett J; Nefedova Y; Gabrilovich DI
Cell Rep; 2020 Dec; 33(13):108571. PubMed ID: 33378668
[TBL] [Abstract][Full Text] [Related]
18. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P
Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564
[TBL] [Abstract][Full Text] [Related]
19. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
